Skip to main content
Print Save

Qulipta Disease Interactions

There is 1 disease interaction with Qulipta (atogepant).

Major

Atogepant (applies to Qulipta) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Atogepant should be avoided in patients with severe hepatic impairment. For patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe hepatic impairment (Child-Pugh Class C), total atogepant exposure increased by 24%, 15%, and 38%, respectively. During clinical trials, cases of elevated transaminase levels to over 3 times the upper limit of normal were temporally associated with atogepant use; these cases were asymptomatic and resolved within 8 weeks of discontinuation.

References

  1. "Product Information. Qulipta (atogepant)." AbbVie US LLC (2021):

Qulipta drug interactions

There are 172 drug interactions with Qulipta (atogepant).

Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer